0000000000536968

AUTHOR

A. Giampaolo

showing 2 related works from this author

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

2018

Background Albuminuria has been classically considered a marker of kidney damage progression in diabetic patients and it is routinely assessed to monitor kidney function. However, the role of a mild GFR reduction on the development of stage ≥3 CKD has been less explored in type 1 diabetes mellitus (T1DM) patients. Aim of the present study was to evaluate the prognostic role of kidney disease measures, namely albuminuria and reduced GFR, on the development of stage ≥3 CKD in a large cohort of patients affected by T1DM. Methods A total of 4284 patients affected by T1DM followed-up at 76 diabetes centers participating to the Italian Association of Clinical Diabetologists (Associazione Medici D…

AdultMaleNephrologymedicine.medical_specialtyendocrine system diseasesRenal function030209 endocrinology & metabolism030204 cardiovascular system & hematologylcsh:RC870-923Kidneyurologic and male genital diseasesGFR03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineDiabetes mellitusmedicineHumansAlbuminuriaDiabetic kidney diseaseKidneyType 1 diabetesurogenital systembusiness.industryIncidence (epidemiology)Middle Agedlcsh:Diseases of the genitourinary system. Urologymedicine.diseasefemale genital diseases and pregnancy complicationsAlbuminuria Diabetic kidney disease GFR NephrologyDiabetes Mellitus Type 1medicine.anatomical_structureItalyNephrologyDisease ProgressionAlbuminuriaFemalemedicine.symptombusinessResearch ArticleFollow-Up StudiesGlomerular Filtration RateKidney disease
researchProduct

Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBi…

2020

Emicizumab has been approved in several countries for regular prophylaxis in patients with congenital haemophilia A and FVIII inhibitors because it substantially reduces their bleeding risk and improves quality of life. However, although significantly less frequent, some breakthrough bleeds may still occur while on emicizumab, requiring treatment with bypassing or other haemostatic agents. Thrombotic complications have been reported with the associated use of activated prothrombin complex concentrates. In addition, when surgery/invasive procedures are needed while on emicizumab, their management requires multidisciplinary competences and direct supervision by experts in the use of this agen…

Factor VIIIFVIII inhibitorSettore BIO/12Antibodies Bispecific Antibodies Monoclonal Humanized Factor VIII Hemophilia A Hemorrhage Hemostatics Humans Italy Quality of LifeFVIII inhibitorsHemorrhageAntibodies Monoclonal HumanizedHemophilia AAntibodiesHemostaticsbypassing agents; emergency; emicizumab; FVIII inhibitors; haemophilia AItalyhemic and lymphatic diseasesMonoclonalEmergencyHaemophilia AAntibodies BispecificQuality of LifeHumansBispecificBypassing agentsEmicizumabHumanizedBypassing agentHaemostasis
researchProduct